| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Zymeworks Inc. (ZYME) has 14 insiders with recent SEC Form 4 filings, including 7 buys and 3 sells. ZYME is classified in the Biotechnology industry within the Health Care sector.
| Role | Insider | Shares | Value | 30d |
|---|---|---|---|---|
| CEO | 257.3K | $6.32M | - | |
| CFO | 178.0K | $4.37M | - | |
| COO | 66.0K | $1.62M | - | |
| Other | 58.1K | $1.43M | - | |
| VP | 36.0K | $885.0K | - |
Buys and sells only
| Date | Insider | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Mar 10, 2023 | Klompas Neil A | President &COO | Sale+OE | 2,977 | $7.83 | $23,297.70 | -14.9% | +10.1% | +44.3% | |
| Jan 20, 2023 | Ecor1 Capital, LLC76 | 10% Owner | Buy | 307,500 | $9.70 | $2,982,733.31 | +1.6% | -1.7% | -1.2% | |
| Jan 18, 2023 | Ecor1 Capital, LLC76 | 10% Owner | Buy | 985,100 | $9.84 | $9,697,526.50 | +3.7% | -0.2% | -1.4% | |
| Jan 11, 2023 | Ecor1 Capital, LLC76 | 10% Owner | Buy | 1,026,300 | $7.67 | $7,874,082.53 | +6.4% | +9.2% | +33.1% | |
| Dec 12, 2022 | Astle Christopher | SVP &Chief Financial Officer | Sale+OE | 887 | $6.01 | $5,330.87 | -40.0% | +37.5% | +53.2% | |
| Nov 10, 2022 | Josephson Neil | Chief Medical Officer | Sale+OE | 2,475 | $8.10 | $20,045.03 | -14.6% | +9.9% | -11.1% |